10/11/2026
FDA seeks public input on ibogaine trial safety
Ibogaine trials for opioid use disorder face scrutiny over safety.
Topic archive
department of health and human services
11 stories
10/9/2026
FDA faces internal dissent over HHS peptide legalization
HHS plans to allow unapproved peptides, sparking FDA staff concerns.
10/6/2026
FDA seeks public input on ibogaine trial design
Request focuses on safety, dosing, and oversight for early-phase trials.
8/19/2026
Trump pushes ibogaine treatment for veterans
Trump's administration advances psychedelic therapies for PTSD and TBI in veterans.
8/19/2026
Psyence BioMed supports U.S. push for ibogaine development
U.S. federal actions could accelerate ibogaine's medical potential
8/19/2026
Trump highlights ibogaine in executive order on psychedelics
The executive order aims to expedite research on ibogaine and other psychedelics.
8/19/2026
Trump highlights ibogaine research in executive order
Ibogaine, a psychedelic drug, gains federal attention for treating addiction.
8/19/2026
University of Miami submits ibogaine application to federal authorities
Trump announces transfer of ibogaine investigational drug application to accelerate research.
7/24/2026
Heidi Overton's role in Trump's ibogaine policy
White House adviser Heidi Overton shapes ibogaine policy amid internal disputes.
7/24/2026
Joe Rogan's ibogaine advocacy sparks White House tension
Rogan's push for ibogaine approval led to conflict with a key Trump aide.
7/22/2026
Federal agencies advance psychedelic therapy post-Trump order
Trump's 2026 executive order boosts psychedelic research funding and collaboration.